JAK Inhibitors for ET and PV: What Have We Learned So Far

JAK Inhibitors for ET and PV: What Have We Learned So Far

imedex

3 years
670 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
In this presentation from the 2016 US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, held August 26-27 in Alexandria, VA, Dr. Ellen Ritchie discusses what we have learned thus far regarding the use of JAK inhibitors for the treatment of essential thrombocythemia (ET) and polycythemia vera (PV). Earn accreditation for a related activity at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7221 © 2016 Imedex, LLC.
Up Next Autoplay
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Category: Liver Cancer
0 Views
imedex 38 minutes
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Category: Liver Cancer
0 Views
imedex 38 minutes
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Category: Liver Cancer
0 Views
imedex 38 minutes
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Category: Liver Cancer
0 Views
imedex 38 minutes
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Category: Liver Cancer
0 Views
imedex 39 minutes
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Category: Liver Cancer
1 Views
imedex 44 minutes
IASLC on Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection
IASLC on Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection
Category: Non-Small Cell Lung Cancer
10 Views
University of Torino 1 day
Oncopeptides to Highlight Data from Melflufen Clinical Program in Multiple Myeloma and AL Amyloidosis in Six Presentations at ASH Annual Meeting 2019
Oncopeptides to Highlight Data from Melflufen Clinical Program in Multiple Myeloma and AL Amyloidosis in Six Presentations at ASH Annual Meeting 2019
Category: News
19 Views
Cancer-News 1 day
Phase I/II Study of Ruxolitinib @SeattleCCA @heidigraydrezn5 @UWashOBGYN
Phase I/II Study of Ruxolitinib @SeattleCCA @heidigraydrezn5 @UWashOBGYN
Category: Ovarian Cancer
22 Views
SeattleCCA 6 days
CDX-1140 Shows Clinical and Biological Efficacy in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Studies
CDX-1140 Shows Clinical and Biological Efficacy in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Studies
Category: Immunotherapy
12 Views
Cancer-News 6 days